{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-020183","form_type":"8-K","ticker":"JANX","cik":"0001817713","company_name":"Janux Therapeutics, Inc.","filed_at":"2024-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.662063+00:00","generated_at":"2026-06-05T15:37:20.042392+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Janux announces encouraging safety/efficacy data for JANX007 in mCRPC and JANX008 in solid tumors","bullets":["JANX007: 5/6 (83%) PSA50 declines at step dose ≥0.2 mg; 10/18 (56%) at ≥0.1 mg; no Grade 3+ CRS.","JANX008: NSCLC subject achieved confirmed PR with 100% target lung lesion reduction and elimination of liver metastasis; no CRS or TRAEs.","JANX008: No Grade 2+ CRS, no treatment-related SAEs or DLTs across 11 heavily pretreated patients across 4 tumor types.","Janux hosting virtual investor event today at 4:30 PM ET to discuss data."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-020183","json":"https://secwatch.observer/filing/0000950170-24-020183.json","markdown":"https://secwatch.observer/filing/0000950170-24-020183.md","text":"https://secwatch.observer/filing/0000950170-24-020183.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817713/000095017024020183/0000950170-24-020183-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817713/000095017024020183/janx-20240226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T15:37:20.042392+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}